Credentialing Ovarian Cancer Models in the Context of the Dualistic Pathway Paradigm

在二元途径范式背景下验证卵巢癌模型

基本信息

批准号：
9104709
负责人：
KATHLEEN R. CHO
金额：
$ 47.18万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-01 至 2019-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9104709
关键词：
Adenoviruses Alleles Bilateral Biological Models Biology Blood Circulation Cancer Model Carcinoma Categories Cervical Cessation of life Characteristics Chromatin Remodeling Factor Chromosomal Instability Clinical Credentialing Data Defect Diagnosis Disease Distal Early Diagnosis Early treatment Epithelium Excision Functional disorder Funding Opportunities Gene Expression Gene Mutation Genes Genetic Genetically Engineered Mouse Goals Human Human Biology Image Indolent Inherited Injection of therapeutic agent Lesion Liquid substance Location LoxP-flanked allele Malignant Female Reproductive System Neoplasm Malignant neoplasm of ovary Mammalian Oviducts Metastatic to Methods Microscopic Modeling Molecular Molecular Profiling Monitor Mouse Strains Mus Mutation Neoplasm Metastasis Operative Surgical Procedures Ovarian Ovarian Carcinoma Ovarian Endometrioid Adenocarcinoma Pap smear Pathogenesis Pathologic Pathway interactions Predisposition Prevention Primary Lesion Reporter Reporting Resolution Risk Reduction Salpingo-Oophorectomy Sampling Screening for Ovarian Cancer Serous Signal Pathway Signal Transduction Somatic Mutation Specimen Staging Surface System TP53 gene Tamoxifen Technology Testing Transgenic Organisms Translational Research Tumor Biology Tumor Suppressor Genes Tumor-Derived United States Vaginal Douching Validation Woman base bioluminescence imaging cancer risk cohort digital digital imaging improved in vivo intraperitoneal mouse model mutant next generation sequencing oncology preclinical study promoter prophylactic public health relevance recombinase response tool translational study tumor tumor DNA tumor progression

项目摘要

DESCRIPTION (provided by applicant): A dualistic model of ovarian cancer (OvCa) pathogenesis has recently been proposed in which OvCas can be broadly divided into two categories. Type I OvCas are considered to be low-grade, relatively indolent tumors, while Type II OvCas are high-grade, biologically aggressive tumors from their outset. Recent studies suggest the most common and lethal type of "ovarian" cancer, high-grade serous carcinoma (HGSC), usually arises in fallopian tube epithelium (FTE) rather than the ovarian surface epithelium (OSE). HGSCs display a high level of chromosomal instability and virtually all harbor somatic TP53 mutations, which occur very early in HGSC pathgenesis. Dysfunction of the RB and BRCA pathways is also common in HGSCs. Genetic instability in the early lesions presumably enhances the likelihood that somatic mutations conferring metastatic potential will be acquired. Thus, women with HGSCs typically have small primary lesions and widespread metastases at diagnosis. A current challenge is to detect early-stage HGSCs while they are curable with surgical resection. Genetically engineered mouse models (GEMMs) of OvCa that closely recapitulate their human tumor counterparts provide excellent in vivo systems with which to study tumor biology and perform pre-clinical studies aimed at improving prevention, early detection, and therapy for OvCa. Several GEMMs of OvCa based on OSE transformation have been developed and used in translational studies. More recently, a few models based on transformation of the FTE have been reported. It is not yet known whether oviductal (mouse fallopian tube) models of OvCa are superior to those arising from the OSE with respect to how well they recapitulate the biology of human OvCas or their utility for translational applications. We have developed a new GEMM that employs the Ovgp1 promoter to direct expression of Tamoxifen (TAM)-inducible Cre recombinase in the FTE. Ovgp1-iCreERT2 mice that also carry floxed alleles of tumor suppressor genes that are characteristically inactivated in ovarian endometrioid carcinoma (OEC, prototypical Type I tumor) and HGSC (prototypical Type II tumor) can be induced to form tumors in the FTE following treatment with TAM, or tumors arising in the OSE following ovarian bursal injection of adenovirus expressing Cre. The overarching goal of this funding opportunity is to enhance applicability of mouse models for translational research. Toward that end, we will pursue the following Specific Aims: 1) To credential GEMMs of OvCa arising from FTE- transformation as superior to those arising from OSE-transformation in terms of their morphological and molecular similarity to their human OvCa counterparts; and 2) To test a new tool strain for early detection of oviductal HGSCs based on cervical-vaginal lavage (murine Pap test). Comprehensive gene expression and mutation data with matched high-resolution digital images of murine OECs and HGSCs will be shared at the Oncology Models Forum via the NCIP Hub platform.

描述（通过应用程序证明）：卵巢癌的二元模型（OVCA）分为两类。高度的浆液性癌（HGSC），通常在输卵管上皮（FTE）中，而不是卵巢表面上皮（OSE）诊断的广泛转移已经开发并尚不知道Oviductal（小鼠瀑布管）模型是否优于由OSE产生的，而我们是人类卵子的生物学或转化应用的使用情况OVGP1启动子在FTE中直接表达（TAM）诱导的CRE重组酶。可以在用TAM治疗后诱导FTE中的表现，或者在表达CRE的卵巢囊病后出现的肿瘤最后，我们将为以下特定的AM插入：1）凭借其形态和分子与人类ovca nterparts相比，由FTE变形而产生的OVCA凭证；耳朵耳朵耳朵耳朵耳朵耳朵耳朵耳朵耳朵的早期检测基于颈椎灌注（Murine Pap Test）的卵子HGSC（Murine Pap Test）。通过NCIP集线器平台在Toenco Logy模型论坛上进行。